Catherine Spier - Concepedia

Author

Catherine Spier

Also Known As

C M Spier, C Spier, C. M Spier, C. M. Spier, C. Spier, C.M. Spier, Catherine M Spier, Catherine M. Spier, Catherine Spier

107

Publications

5.2K

Citations

H-Index

Concepts

All Affiliations

University of Arizona Fred Hutch Cancer Center University of Arizona Cancer Center University of Rochester Medical Center University of Rochester

About

Catherine Spier is an author at University of Arizona specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	1.3K
2	Cell Biology	3	3	119
3	Health Sciences	2	2	439
4	Public Health	1	1	22
5	Biochemistry	1	1	41

Catherine Spier

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma Thomas P. Miller, Steve Dahlberg, J. Robert Cassady, New England Journal of Medicine	1998	1K
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. TP Miller, Thomas M. Grogan, William S. Dalton, Journal of Clinical Oncology PathologyPharmacotherapyVerapamil ResultsTumor BiologyDrug Resistance	1991	385
Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity Tyler J. Ripperger, Jennifer L. Uhrlaub, Makiko Watanabe, Immunity VaccinationViral EvolutionViral DiagnosticsMedicineVaccine Target	2020	355
Plasma cells in multiple myeloma express a natural killer cell- associated antigen: CD56 (NKH-1; Leu-19) Benjamin Van Camp, BG Durie, Catherine Spier, Blood	1990	309
Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014 Daniel O. Persky, Joseph M. Unger, Catherine Spier, Journal of Clinical Oncology	2008	290
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. Alan F. List, Catherine Spier, John P. Greer, Journal of Clinical Oncology	1993	280
Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus <sup>131</sup> Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016 Oliver W. Press, Joseph M. Unger, Lisa M. Rimsza, Journal of Clinical Oncology	2012	172
Expression of the multidrug resistance gene product (P‐glycoprotein) in myelodysplasia is associated with a stem cell phenotype Alan F. List, Catherine Spier, A. C. Cline, British Journal of Haematology	1991	124
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108 Paul M. Barr, Hongli Li, Catherine Spier, Journal of Clinical Oncology	2015	111
HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. TP Miller, Scott M. Lippman, Catherine Spier, Journal of Clinical Investigation HistocompatibilityImmunologyPathologyImmune PhenotypeImmunotherapy	1988	100

Page 1